The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 15, Issue 4
|The correlation between medical tourism and biotechnology||PDF|
|David G Vequist IV, Erika Valdez|
|The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interview||PDF|
Legal and Regulatory Updates
|Legal and Regulatory Update||PDF|
|Gerry Kamstra, John Wilkinson|
In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s genome is sequenced and drug prescriptions are based on your genetic makeup, and argues that personalized medicine will be the defining paradigm for discovering and developing drugs of the future.
To put these videos into context, consider the recent report which found that a majority of patients receiving Herceptin had not been tested for HER-2 overexpression — Herceptin is a targeted drug intended primarily for patients overexpressing HER-2. The apparently common prescription of Herceptin independent of it’s diagnostic test suggests that the practice of medicine needs to adapt to keep pace with scientific advance.
DCbiotech is a high-level networking group based in Washington DC. The objective is to bring together individuals working in, or serving, the biotechnology sector in Washington DC.
For more information, please visit http://www.DCbiotech.com . The first meeting is scheduled for September 15th. Full details and the RSVP form are available here.
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in September 2009
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|FARESTON||Gtx Inc||toremifene citrate||4,696,949||Sep 29, 2009|
|FELBATOL||Meda Pharms||felbamate||4,978,680||Sep 26, 2009|
|FELBATOL||Meda Pharms||felbamate||5,082,861||Sep 26, 2009|
|GLUCOTROL XL||Pfizer||glipizide||5,024,843||Sep 5, 2009|
|GLUCOTROL XL||Pfizer||glipizide||5,091,190||Sep 5, 2009|
|IMPLANON||Organon Usa Inc||etonogestrel||5,150,718||Sep 29, 2009|
|NEORAL||Novartis||cyclosporine||5,866,159||Sep 13, 2009|
|NEORAL||Novartis||cyclosporine||5,916,589||Sep 13, 2009|
|NEORAL||Novartis||cyclosporine||5,962,014||Sep 13, 2009|
|NEORAL||Novartis||cyclosporine||5,962,017||Sep 13, 2009|
|NEORAL||Novartis||cyclosporine||6,007,840||Sep 13, 2009|
|NEORAL||Novartis||cyclosporine||6,024,978||Sep 13, 2009|
|PRIMAXIN||Merck||cilastatin sodium; imipenem||5,147,868||Sep 15, 2009|
|STARLIX||Novartis||nateglinide||RE34878||Sep 8, 2009|
|TOBRADEX||Alcon||dexamethasone; tobramycin||5,149,694||Sep 22, 2009|
|TOBRADEX ST||Alcon||dexamethasone; tobramycin||5,149,694||Sep 22, 2009|
|TOBRASONE||Alcon||fluorometholone acetate; tobramycin||5,149,693||Sep 22, 2009|
|XALATAN||Pharmacia And Upjohn||latanoprost||6,429,226||Sep 6, 2009|
Courtesy of DrugPatentWatch.com
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.